Mortality due to cervical cancer can be reduced by prevention, early detection & treatment.
Vaccination may be started as early as 9 years old.
Vaccination may reduce the incidence of HPV-related disease.
Screening for cervical cancer after vaccination is still recommended because only 70% of the virus types associated w/ invasive cervical cancer consist of HPV 16 & 18 types & women may not be entirely protected if they have been infected w/ other HPV types prior to vaccination.
Young Singaporean women are likely to get themselves immunized against human papillomavirus (HPV) with the motivation to protect their own health, positive information about the vaccine and parental encouragement, as reported in a recent qualitative study.
Human papillomavirus (HPV) vaccination significantly reduces the frequency of genital HPV 16 and 18 infections and cervical intraepithelial neoplasia grade 2+ (CIN2+) in young women and shows signs of herd effects with a reduced frequency of anogenital warts in both young women and men, a recent study showed.
It appears that women who tend to avoid Pap smear screening in Singapore are those who are younger, of Malay ethnicity and who lack confidence in the effectiveness of the procedure as a prevention measure against cervical cancer, a study reports.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
Endocervical sampling with a new fabric-based curette device reduces the number of “inadequate” specimens and hence, the need for repeat biopsies compared with conventional metal scraping, reveals a recent study.
Dr Ravichandran Nadarajah, a consultant at the Department of Obstetrics & Gynaecology, Singapore General Hospital, speaks to Roshini Claire Anthony on the importance of early diagnosis and prevention of cervical cancer.
The addition of ibandronate to adjuvant hormonal therapy provides no benefit to postmenopausal women with HR-positive breast cancer, according to early results from the phase III TEAM IIB trial (BOOG 2006-4)*.